Results 181 to 190 of about 1,570,861 (237)

A Robust Deep Temporal Causal Discovery Platform for Single‐Cell Gene Regulatory Network Reconstruction

Advanced Intelligent Discovery, EarlyView.
scTIGER2.0 is a deep‐learning framework that infers gene regulatory networks from single‐cell RNA sequencing data. By integrating correlation, pseudotime ordering, deep learning and bootstrap‐based significance testing, it reduces false positives and reveals directional gene interactions.
Nishi Gupta, Madison Dautle, Shaoqiang Zhang, Yong Chen   +3 more
wiley   +1 more source

Rapid Development of Unclassified Myeloid Lineage Acute Leukaemia With Trisomy 6 and U2AF1 Mutation. [PDF]

J Cell Mol Med
Markiewicz M, Kopacz A, Blajer-Olszewska B, Mazur M, Warzybok K, Szarawarska M, Wojtaszewska M, Moskwa M, Dudycz D, Schwarz E, Kosior K, Lewandowski K.   +11 more
europepmc   +1 more source

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

Advanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

Factors influencing reproductive concerns and their correlation with quality of life among adolescents and young adults with acute leukaemia in Hunan province, China: a cross-sectional study. [PDF]

BMJ Open
Zhang Y, Zhang Z, Zhang W, Zeng X, Ma G, Xiao Y, Wong CL, Chan CWH, Gu C.   +8 more
europepmc   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, EarlyView.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

Impact of COVID-19 on the Clinical Characteristics and Outcomes of Patients with Acute Leukaemia: An academic centre experience. [PDF]

Sultan Qaboos Univ Med J
Al-Kindi AY, Al-Busaidi T, Al-Kindi Y, Al-Bulushi F, Al-Hanini M, Al-Bakri M, Al-Khabori M.   +6 more
europepmc   +1 more source

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative strategy for acute myeloid leukemia (AML), but the impact of HLA disparity in the era of posttransplant cyclophosphamide (PTCy) and reduced‐toxicity conditioning remains unclear. We performed an EBMT registry study including 275 adult AML patients in first
Daniele Avenoso, Mirko Farina, Michele Malagola, Yves Chalandon, Giorgia Saporiti, Annalisa Imovilli, Enrico Derenzini, Peter Remenyi, Massimo Martino, Maija Itala‐Remes, Renato Fanin, Didier Blaise, Desiree Kunadt, Arancha Bermudez Rodriguez, Franca Fagioli, Thomas Schroeder, Irene Cavattoni, Maud Ngoya, Mohamed Houhou, Mohamad Mohty, Eolia Brissot, Fabio Ciceri   +21 more
wiley   +1 more source

Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions. [PDF]

Int J Mol Sci
Capelletti MM, Montini O, Ruini E, Tettamanti S, Savino AM, Sarno J.   +5 more
europepmc   +1 more source

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, EarlyView.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

Acute Leukaemia following Dengue Infection in Nepalese Patients: A Report of Two Cases. [PDF]

Case Rep Hematol
Agrawal A, Lamichhane P, Baral R, Thapaliya S.   +3 more
europepmc   +1 more source